Meaningful psoriasis improvement (PASI ≥50%, reduced plaque burden, decreased pruritus and impact on quality of life) is reported in 40–55% of treated cohorts over 12 weeks. Clearance rates (PASI 90–100%) are lower than with modern anti-TNF or anti-IL-17 biologics, ranging 15–25%. Responders tend to be moderate-severity (PASI 10–20 at baseline); severe or treatment-refractory phenotypes show variable outcomes. Stability of improvement depends on disease aetiology and concurrent stressor management.
Clinical trial data spans phase I safety and small phase II efficacy assessments involving 50–200 participants per study. Representative trials report psoriasis area and severity index (PASI) improvements of 50% or greater in 35–50% of infused cohorts over 12 weeks, with some achieving PASI 75 or 90 (near-complete clearance) in 20–30%. Erythema, scaling, and infiltration scores improve more consistently than pruritus. Remission duration in responders extends 3–8 months post-infusion; re-treatment may be required for sustained control. Compared to anti-TNF or anti-IL-17 biologics, MSC efficacy appears modest but comparable in blinded assessments.
我是候选人吗？ → · Psoriasis: full overview → · 银屑病成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估